Tevogen Bio Holdings IncTVGN
Price$6.72

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$21.6MTTM through 30 Jun 2026
Free Cash Flow -$11.6MTTM through 30 Jun 2026

Margins

Current

Returns

243.1%ROE

Balance Sheet Health

Debt / Equity-0.91x
Current Ratio0.22x
Net Debt$5.5M
Cash & Equivalents$0

Quality Metrics

Altman Z-Score-58.43
Piotroski F-Score2 / 9
Earnings-Beat Rate50.0%

Multi-Year Trend

Diluted EPS-$6.29TTM
'23'24'25
FY2025: $-7.91

Dividend

No dividend

Capital Allocation

R&D Spend$11.6M

Segment Performance

No segment data available.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.